Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: December 2010

13 - Chronic myeloid leukemia

from Part 2 - Hematological malignancies
References
Nowell, PC, Hungerford, DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497–501.
Heisterkamp, N, Groffen, J, Stephenson, JRet al. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature 1982;299(5885):747–9.
Daley, GQ, Etten, RA, Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247(4944):824–30.
Goldman, JM, Melo, JV. Chronic myeloid leukemia – advances in biology and new approaches to treatment. New Engl J Med 2003;349(15):1451–64.
Druker, BJ, Tamura, S, Buchdunger, Eet al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2(5):561–6.
O'Brien, SG, Guilhot, F, Larson, RAet al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003;348(11):994–1004.
Sawyers, CL, Hochhaus, A, Feldman, Eet al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99(10):3530–9.
Druker, BJ, Talpaz, M, Resta, DJet al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001;344(14):1031–7.
Vardiman, JW, Melo, JV, Baccarani, M, Thiele, J. Chronic myelogenous leukaemia, BCR-ABL1 positive. In Jaffe, ES, Harris, NL, Stein, H, Vardiman, JW (eds.), Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:32–7.
Faderl, S, Talpaz, M, Estrov, Z, Kantarjian, HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131(3):207–19.
Berger, U, Maywald, O, Pfirrmann, Met al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 2005;19(6):984–9.
Corso, A, Lazzarino, M, Morra, Eet al. Chronic myelogenous leukemia and exposure to ionizing radiation – a retrospective study of 443 patients. Ann Hematol 1995;70(2):79–82.
Beillard, E, Pallisgaard, N, Velden, VHet al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia 2003;17(12):2474–86.
Saglio, G, Pane, F, Gottardi, Eet al. Consistent amounts of acute leukemia-associated P190 BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis. Blood 1996;87(3):1075–80.
Melo, JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88(7):2375–84.
Melo, JV, Myint, H, Galton, DA, Goldman, JM. P190 BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?Leukemia 1994;8(1):208–11.
Pane, F, Frigeri, F, Sindona, Met al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996;88(7):2410–14.
Baccarini, M, Cortes, J, Pane, Fet al. Chronic myeloid leukaemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27(35):6041–51.
Sokal, JE, Cox, EB, Baccarani, Met al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984;63(4):789–99.
Hasford, J, Pfirrmann, M, Hehlmann, Ret al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90(11):850–8.
Rosti, G, Trabacchi, E, Bassi, Set al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003;88(3):256–9.
Hasford, J, Pfirrmann, M, Hehlmann, Ret al. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. Semin Hematol 2003;40(1):4–12.
Bonifazi, F, Vivo, A, Rosti, Get al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98(10):3074–81.
Druker, BJ, Guilhot, F, O'Brien, SGet al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med 2006;355(23):2408–17.
Branford, S, Rudzki, Z, Harper, Aet al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003;17(12):2401–9.
Kantarjian, H, O'Brien, S, Shan, Jet al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?Cancer 2008;112(4):837–45.
Roy, L, Guilhot, J, Krahnke, Tet al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108(5):1478–84.
Kantarjian, HM, O'Brien, S, Cortes, Jet al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003;98(12):2636–42.
Kantarjian, HM, Talpaz, M, O'Brien, Set al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006;108(6):1835–40.
Lavallade, H, Milojkovic, D, Khorashad, JSet al. Outcome, prognostic factors and long-term follow-up in 207 chronic phase CML patients receiving front-line imatinib 400 mg at a single institution. ASH Annual Meeting Abstr 2007;110(11):1045.
Lucas, CM, Wang, L, Austin, GMet al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008;22(10):1963–6.
Kantarjian, H, Talpaz, M, O'Brien, Set al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103(8):2873–8.
Cortes, J, Baccarani, M, Guilhot, Fet al. A phase iii, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (im) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study. ASH Annual Meeting Abstr 2008;112(11):335.
Cortes, J, O'Brien, S, Jones, Det al. Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). ASH Annual Meeting Abstr 2008;112(11):446.
Cortes, J, O'Brien, S, Borthakur, Get al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annual Meeting Abstr 2008;112(11):182.
Lavallade, H, Apperley, JF, Khorashad, JSet al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26(20):3358–63.
Apperley, JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8(11):1018–29.
Silver, RT, Woolf, SH, Hehlmann, Ret al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94(5):1517–36.
Gratwohl, A, Hermans, J, Goldman, JMet al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352(9134):1087–92.
Crawley, C, Szydlo, R, Lalancette, Met al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106(9):2969–76.
Goldman, JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007;110(8):2828–37.
Hughes, TP, Kaeda, J, Branford, Set al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med 2003;349(15):1423–32.
Lugli, A, Ebnoether, M, Cogliatti, SBet al. Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. Hum Pathol 2005;36(1):91–100.
Cortes, JE, Talpaz, M, Giles, Fet al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101(10):3794–800.
Bumm, T, Muller, C, Al-Ali, HKet al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101(5):1941–9.
O'Dwyer, ME, Gatter, KM, Loriaux, Met al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17(3):481–7.
Bacher, U, Hochhaus, A, Berger, Uet al. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 2005;19(3):460–3.
Deininger, MW, Cortes, J, Paquette, Ret al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007;110(7):1509–19.
Hughes, T, Deininger, M, Hochhaus, Aet al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108(1):28–37.
Cross, NC, Hughes, TP, Hochhaus, A, Goldman, JM. International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res 2008;32(3):505–6.
Gorre, ME, Mohammed, M, Ellwood, Ket al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876–80.
Shah, NP, Nicoll, JM, Nagar, Bet al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2(2):117–25.
Branford, S, Rudzki, Z, Walsh, Set al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99(9):3472–5.
Bubnoff, N, Schneller, F, Peschel, C, Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002;359(9305):487–91.
O'Hare, T, Eide, CA, Deininger, MW. BCR-ABL kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110(7):2242–9.
Pavlovsky, C, Kantarjian, H, Cortes, JE. First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol 2009;84(5):287–93.
Hochhaus, A, Hughes, T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004;18(3):641–56, ix.
Press, RD, Willis, SG, Laudadio, J, Mauro, MJ, Deininger, MW. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114(13):2598–605.
Sherbenou, DW, Wong, MJ, Humayun, Aet al. In chronic myeloid leukemia (CML) patients with complete cytogenetic response to imatinib, BCR-ABL kinase domain mutations are relatively rare and not consistently associated with subsequent relapse. ASH Annual Meeting Abstr 2005;106(11):434.
Jabbour, E, Kantarjian, H, Jones, Det al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20(10):1767–73.
Gratwohl, A, Brand, R, Apperley, Jet al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91(4):513–21.
Kantarjian, H, Schiffer, C, Jones, D, Cortes, J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111(4):1774–80.